ValiRx PLC Shareholder Communications (2408W)

TIDMVAL

RNS Number : 2408W

ValiRx PLC

17 August 2022

17 August 2022

ValiRx PLC ("ValiRx" or the "Company")

Shareholder Communications

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health is pleased to announce the appointment of strategic marketing and PR agency, V Formation Limited and the appointment of Dr Adam Hargreaves as a shareholder representative. The appointments represent the Company's continued strategy to improve and enhance communications with its shareholders.

V Formation Limited is a Nottingham-based public relations and marketing communications agency that specialises in supporting clients in the life sciences sector, ensuring that news and corporate development updates are optimised and communicated in a clear, transparent and precise manner. V Formation will liaise closely with Dr Hargreaves in his role as shareholder representative, as well as with ValiRx's Nominated Adviser and brokers, to improve the interpretation and dissemination of Company newsflow following publication via a regulatory information provider.

Dr Adam Hargreaves has agreed to become a shareholder representative to help improve communications between the Company and shareholders. The Company's overall policy on shareholder communications is unchanged, with written quarterly updates and quarterly live Q&A events continuing. However, shareholders can additionally communicate with Dr Hargreaves directly to seek clarification of any details that have been publicly announced, or through a shareholder community. Dr Hargreaves will have regular interaction with the Company to ensure that shareholders' views are fully represented to the Board. Shareholders wishing to communicate directly with Board members are welcome to do so, with a prompt response when possible.

*** ENDS ***

For more information, please contact:

 
 ValiRx plc                                        Tel: [phone] 
                                                    796496 
  Dr Suzanne Dilly, CEO                             www.valirx.com 
                                                    [e-mail] 
  Dr Adam Hargreaves, Shareholder Representative 
                                                    [e-mail] 
 V Formation (Public Relations) 
                                                     Contact details 
  Lucy Wharton - Senior PR Executive                 www.vformation.biz 
  Sue Carr - Director                                [e-mail] 
                                                     [e-mail] 
                                                     [phone] 
                                                  ---------------------------------- 
 Cairn Financial Advisers LLP (Nominated           Tel: +44 (0) 20 
  Adviser)                                          7213 088 
 
  Liam Murray/Jo Turner/Ludovico Lazzaretti 
                                                  ---------------------------------- 
 Cenkos Securities Limited (Joint Broker)          Tel: +44 (0) 20 
                                                    7397 8900 
  Russell Kerr/Michael Johnson (Sales) 
 
  Callum Davidson/Giles Balleny (Corporate 
  Finance) 
                                                  ---------------------------------- 
 Turner Pope Investments (Joint Broker)            Tel: +44 (0) 20 
  James Pope / Andy Thacker                         3657 0050 
                                                  ---------------------------------- 
 

Notes for Editors

About ValiRx

ValiRx accelerates the development of treatments in oncology and women's health to improve patient lives. We provide the scientific, financial and commercial framework towards enabling rapid translation of innovative science into clinical development.

With our extensive and proven experience in research and drug development, we select and incubate promising novel drug candidates and guide them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

Integrating science and business

We connect diverse disciplines across scientific, technical and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. We work closely with our selected collaborators and leverage the combined expertise required for science to advance.

Lead candidates from our portfolio are out-licensed or partnered with investors through ValiRx subsidiary

companies for further clinical development and commercialisation.   https://www.valirx.com/ 

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

About V Formation

V Formation is an established marketing and PR agency based at BioCity Nottingham. The team of experienced marketing and PR consultants deliver inspiring, insightful and supportive marketing advice, strategy and tactics to take businesses closer to their clients and help them find their competitive edge.

V Formation works with ambitious SMEs in the life sciences and high-tech sectors, professional services firms and family businesses. It provides in-house marketing and support, guidance on strategic direction and assistance with tactical marketing and PR. The company's directors are Sue Carr and Hilary Campton.

For more information: www.vformation.biz or 0115 822 6364

Cautionary statement

Certain statements made in this announcement are forward-looking statements. Such statements are based on current expectations and assumptions and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially from any expected future events or results expressed or implied in these forward-looking statements. Persons receiving this announcement should not place undue reliance on forward-looking statements. Unless otherwise required by applicable law, regulation or accounting standard, the Company does not undertake to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCBIGDIISBDGDL

(END) Dow Jones Newswires

August 17, 2022 02:00 ET (06:00 GMT)